Abstract
Ricin is one of the most potent and lethal toxins known to which there is no available antidote. Currently, the most promising therapy is based on neutralizing antibodies elicited by active vaccination or given passively. Here, detailed protocols are provided for the production of two ricin holotoxin-based vaccines: monomerized subunit-based vaccine, and a formaldehyde-based ricin toxoid vaccine. Both vaccines were found to be stable with no toxic activity reversion even after long-term storage while eliciting high anti-ricin antibody titers possessing a potent neutralizing activity. The use of these vaccines is highly suitable for both the production of sera that can be used in passive protection experiments and immunization aimed to isolate potent anti-ricin monoclonal antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Olsnes S, Kozlov JV (2001) Ricin. Toxicon 39:1723–1728
O’Hara JM, Yermakova A, Mantis NJ (2011) Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr Top Microbiol Immunol 357:209–241
Vance DJ, Tremblay JM, Mantis NJ, Shoemaker CB (2013) Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin. J Biol Chem 288:36538–36547
Yermakova A, Mantis NJ (2011) Protective immunity to ricin toxin conferred by antibodies against the toxin’s binding subunit (RTB). Vaccine 29:7925–7935
Cohen A, Mechaly A, Sabo T, Alcalay R et al (2014) Characterization and epitope mapping of the polyclonal antibody repertoire elicited by ricin-holotoxin based vaccination. Clin Vaccine Immunol 21:1534–1540
Gal Y, Mazor O, Alcalay R, Seliger N et al (2014) Antibody/doxycycline combined therapy for pulmonary ricinosis: attenuation of inflammation improves survival of ricin-intoxicated mice. Toxicol Rep 1:496–504
Maddaloni M, Cooke C, Wilkinson R, Stout AV et al (2004) Immunological characteristics associated with the protective efficacy of antibodies to ricin. J Immunol 172:6221–6228
Pincus SH, Das A, Song K, Maresh GA et al (2014) Role of Fc in antibody-mediated protection from ricin toxin. Toxins 6:1512–1525
Pratt TS, Pincus SH, Hale ML, Moreira AL et al (2007) Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp Lung Res 33:459–481
Griffiths GD, Bailey SC, Hambrook JL, Keyte M et al (1997) Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 15:1933–1939
Griffiths GD, Phillips GJ, Bailey SC (1999) Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17:2562–2568
Kende M, Yan C, Hewetson J, Frick MA et al (2002) Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 20:1681–1691
Yan C, Rill WL, Malli R, Hewetson J et al (1996) Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 14:1031–1038
Griffiths GD, Phillips GJ, Holley J (2007) Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal Toxicol 19:873–887
Yan C, Rill WL, Malli R, Hewetson J et al (1995) Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers. Vaccine 13:645–651
Kronman C, Velan B, Gozes Y, Leitner M et al (1992) Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene 121:295–304
Acknowledgements
We thank Dr. Eytan Elhanany, Dr. Yoav Gal, Ron Alcalay, Nehama Seliger, and Sharon Erlich for contributing to the development of protocols.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Sabo, T., Kronman, C., Mazor, O. (2016). Ricin-Holotoxin-Based Vaccines: Induction of Potent Ricin-Neutralizing Antibodies. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_38
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3387-7_38
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3385-3
Online ISBN: 978-1-4939-3387-7
eBook Packages: Springer Protocols